In recent years, the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are transforming the way diseases are treated but are also aiming to cure entirely new patient populations. 2021 saw record-breaking investments across the board, with a 16% increase from the previous year, totaling $23.1billion raised. However, the question remains as to whether this will continue in 2022. As public markets adjust and the economy recovers in early 2022, investments in the cell and gene therapy space may plateau.

Anshul Mangal (President, Project Farma) is joined by Dr. Deborah Phippard (CSO, Precision for Medicine) to provide insight into the promising commercial pipeline and ongoing clinical trials in “Cell & Gene Therapies: Opportunities for Innovation”.

CLICK HERE to read the full article.